Published in J Virol on November 01, 2000
A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem (1997) 9.97
Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol (1993) 8.47
NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol (1993) 4.60
Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell (1996) 4.12
Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J Virol (1994) 3.51
Kinetic and structural analyses of hepatitis C virus polyprotein processing. J Virol (1994) 3.35
The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell (1996) 2.81
Substrate phage: selection of protease substrates by monovalent phage display. Science (1993) 2.04
Specificity of the hepatitis C virus NS3 serine protease: effects of substitutions at the 3/4A, 4A/4B, 4B/5A, and 5A/5B cleavage sites on polyprotein processing. J Virol (1994) 1.85
The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J Viral Hepat (1999) 1.58
Molecular model of the specificity pocket of the hepatitis C virus protease: implications for substrate recognition. Proc Natl Acad Sci U S A (1994) 1.57
Activity of purified hepatitis C virus protease NS3 on peptide substrates. J Virol (1996) 1.32
Product inhibition of the hepatitis C virus NS3 protease. Biochemistry (1998) 1.32
Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase. J Virol (1995) 1.31
In vitro activity of hepatitis C virus protease NS3 purified from recombinant Baculovirus-infected Sf9 cells. J Biol Chem (1996) 1.09
Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides. J Virol (1997) 1.07
Modulation of hepatitis C virus NS3 protease and helicase activities through the interaction with NS4A. Biochemistry (1999) 1.06
Random peptide libraries. Curr Opin Biotechnol (1994) 1.05
Substrate specificity of the hepatitis C virus serine protease NS3. J Biol Chem (1997) 1.01
In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotechnol (1998) 0.97
Chimeric Sindbis viruses dependent on the NS3 protease of hepatitis C virus. J Virol (1997) 0.93
Sindbis virus vectors for expression in animal cells. Curr Opin Biotechnol (1996) 0.90
Codon-based mutagenesis using dimer-phosphoramidites. Nucleic Acids Res (1998) 0.90
Selection of functional variants of the NS3-NS4A protease of hepatitis C virus by using chimeric sindbis viruses. J Virol (1999) 0.82
Selection for protease inhibitors using bacteriophage display. Methods Enzymol (1996) 0.77
Conformations of immunoglobulin hypervariable regions. Nature (1990) 5.31
Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci U S A (1995) 5.15
Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci U S A (2007) 3.60
Biosynthesis and biochemical properties of the hepatitis C virus core protein. J Virol (1994) 3.19
Elevated levels of interleukin-6 in unstable angina. Circulation (1996) 2.66
A designed metal-binding protein with a novel fold. Nature (1993) 2.48
Catalytic antibodies. Science (1986) 2.41
Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med (2006) 2.25
A model for the hepatitis C virus envelope glycoprotein E2. Proteins (2000) 2.17
Genome sequences and great expectations. Genome Biol (2000) 1.98
Conformations of the third hypervariable region in the VH domain of immunoglobulins. J Mol Biol (1998) 1.96
Suppression of defective RAS1 and RAS2 functions in yeast by an adenylate cyclase activated by a single amino acid change. EMBO J (1986) 1.90
Haemoglobin switching in human embryos: asynchrony of zeta----alpha and epsilon----gamma-globin switches in primitive and definite erythropoietic lineage. Nature (1985) 1.87
Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. J Virol (2000) 1.70
Molecular mechanisms of human hemoglobin switching: selective undermethylation and expression of globin genes in embryonic, fetal, and adult erythroblasts. Proc Natl Acad Sci U S A (1983) 1.68
The NS2 protein of hepatitis C virus is a transmembrane polypeptide. J Virol (1995) 1.61
Molecular model of the specificity pocket of the hepatitis C virus protease: implications for substrate recognition. Proc Natl Acad Sci U S A (1994) 1.57
Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. J Virol (1998) 1.54
Accentuated response to phenylhydrazine and erythropoietin in mice genetically impaired for their GATA-1 expression (GATA-1(low) mice). Blood (2001) 1.51
Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer (2000) 1.50
The two C/EBP isoforms, IL-6DBP/NF-IL6 and C/EBP delta/NF-IL6 beta, are induced by IL-6 to promote acute phase gene transcription via different mechanisms. Nucleic Acids Res (1993) 1.49
Mimicking of discontinuous epitopes by phage-displayed peptides, I. Epitope mapping of human H ferritin using a phage library of constrained peptides. Gene (1993) 1.47
Palmitylation of viral membrane glycoproteins takes place after exit from the endoplasmic reticulum. J Biol Chem (1989) 1.45
The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. J Mol Biol (1999) 1.44
Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut (2004) 1.42
A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates. Anal Biochem (1996) 1.40
Human embryonic hemopoiesis. Kinetics of progenitors and precursors underlying the yolk sac----liver transition. J Clin Invest (1986) 1.39
Comparative analysis of hematopoietic growth factors released by stromal cells from normal donors or transplanted patients. Blood (1990) 1.38
PUZZLE: a new method for automated protein docking based on surface shape complementarity. J Mol Biol (1994) 1.37
Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation (1998) 1.36
Knowledge, beliefs, and prior screening behavior among blacks and whites reporting for prostate cancer screening. Urology (1995) 1.36
Unrelated placental blood for bone marrow reconstitution: organization of the placental blood program. Blood Cells (1994) 1.35
Role of signal recognition particle in the membrane assembly of Sindbis viral glycoproteins. Eur J Biochem (1984) 1.34
Product inhibition of the hepatitis C virus NS3 protease. Biochemistry (1998) 1.32
A stereospecific cyclization catalyzed by an antibody. Science (1987) 1.31
Progressive inactivation of the expression of an erythroid transcriptional factor in GM- and G-CSF-dependent myeloid cell lines. Nucleic Acids Res (1990) 1.30
Free diffusion to and from the inner nuclear membrane of newly synthesized plasma membrane glycoproteins. J Cell Biol (1987) 1.27
Structure and function of the hepatitis C virus NS3-NS4A serine proteinase. Curr Top Microbiol Immunol (2000) 1.24
Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein. J Virol (2001) 1.24
Embryonic----Fetal Hb switch in humans: studies on erythroid bursts generated by embryonic progenitors from yolk sac and liver. Proc Natl Acad Sci U S A (1984) 1.24
Biochemical characterization of a hepatitis C virus RNA-dependent RNA polymerase mutant lacking the C-terminal hydrophobic sequence. J Gen Virol (2000) 1.19
Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance. Gut (2006) 1.19
Biochemical and immunologic properties of the nonstructural proteins of the hepatitis C virus: implications for development of antiviral agents and vaccines. Semin Liver Dis (2000) 1.18
In vitro study of the NS2-3 protease of hepatitis C virus. J Virol (1997) 1.18
Biochemical fractionation and assembly of the membrane components that mediate nascent chain targeting and translocation. Cell (1991) 1.18
Antibody modeling: implications for engineering and design. Methods (2000) 1.18
International consensus for a definition of disease flare in lupus. Lupus (2010) 1.16
Identification and characterization of a bipotent (erythroid and megakaryocytic) cell precursor from the spleen of phenylhydrazine-treated mice. Blood (2000) 1.14
Health-related quality of life (HR-QOL) and regulatory issues. An assessment of the European Agency for the Evaluation of Medicinal Products (EMEA) recommendations on the use of HR-QOL measures in drug approval. Pharmacoeconomics (2001) 1.14
Members of the zinc finger protein gene family sharing a conserved N-terminal module. Nucleic Acids Res (1991) 1.12
Response to erythropoietin in erythroid subclones of the factor-dependent cell line 32D is determined by translocation of the erythropoietin receptor to the cell surface. Proc Natl Acad Sci U S A (1991) 1.12
Probing the tertiary structure of proteins by limited proteolysis and mass spectrometry: the case of Minibody. Protein Sci (1996) 1.11
The nonstructural proteins of the hepatitis C virus: structure and functions. Biol Chem (1997) 1.10
A zinc binding site in viral serine proteinases. Biochemistry (1996) 1.10
Antibody structure, prediction and redesign. Biophys Chem (1997) 1.10
Identification of biologically active peptides using random libraries displayed on phage. Curr Opin Biotechnol (1995) 1.07
Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry (1998) 1.07
Chemical reactivity at an antibody binding site elicited by mechanistic design of a synthetic antigen. Proc Natl Acad Sci U S A (1986) 1.07
Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 protease. Protein Eng (1997) 1.06
Modulation of hepatitis C virus NS3 protease and helicase activities through the interaction with NS4A. Biochemistry (1999) 1.06
Saturation mutagenesis of the human interleukin 6 receptor-binding site: implications for its three-dimensional structure. Proc Natl Acad Sci U S A (1993) 1.05
In vivo expansion of purified hematopoietic stem cells transplanted in nonablated W/Wv mice. Exp Hematol (1999) 1.03
Mapping epitopes on protein surfaces. Biopolymers (1995) 1.03
Substrate specificity of the hepatitis C virus serine protease NS3. J Biol Chem (1997) 1.01
The metal binding site of the hepatitis C virus NS3 protease. A spectroscopic investigation. J Biol Chem (1998) 1.01
Opposite polarity of virus budding and of viral envelope glycoprotein distribution in epithelial cells derived from different tissues. J Cell Biol (1992) 1.00
A model for recognition of polychlorinated dibenzo-p-dioxins by the aryl hydrocarbon receptor. Eur J Biochem (2002) 1.00
Development of humanized mice for the study of hepatitis C virus infection. Transplant Proc (2006) 1.00
Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies. J Mol Biol (1999) 0.99
Enzyme mimicry by the antiidiotypic antibody approach. Proc Natl Acad Sci U S A (2000) 0.99
Biosynthesis and oligosaccharide structure of human CD8 glycoprotein expressed in a rat epithelial cell line. J Biol Chem (1992) 0.99
Costs of diabetes. A methodological analysis of the literature. Pharmacoeconomics (1999) 0.98
Surface topology of Minibody by selective chemical modifications and mass spectrometry. Protein Sci (1997) 0.98
Yeast mutants temperature-sensitive for growth after random mutagenesis of the chromosomal RAS2 gene and deletion of the RAS1 gene. EMBO J (1988) 0.97
Globin chain synthesis in single erythroid bursts from cord blood: studies on gamma leads to beta and G gamma leads to A gamma switches. Proc Natl Acad Sci U S A (1980) 0.97
Shc mediates IL-6 signaling by interacting with gp130 and Jak2 kinase. J Immunol (1997) 0.97
Conformational changes in the NS3 protease from hepatitis C virus strain Bk monitored by limited proteolysis and mass spectrometry. Protein Sci (1999) 0.97
Bacteriophage lambda display of complex cDNA libraries: a new approach to functional genomics. J Mol Biol (2000) 0.96
Stable and unstable transgene integration sites in the human genome: extinction of the Green Fluorescent Protein transgene in K562 cells. Gene (2000) 0.96
Probability of coding of a DNA sequence: an algorithm to predict translated reading frames from their thermodynamic characteristics. Nucleic Acids Res (1986) 0.96
The cytoarchitecture of sulcal folding in Heschl's sulcus and the temporal cortex in the normal brain and schizophrenia: lamina thickness and cell density. Neurosci Lett (2004) 0.95
Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease. Biochemistry (2000) 0.95
Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial. Pharmacoeconomics (2001) 0.95
Identification and characterization of three classes of erythroid progenitors in human fetal liver. Blood (1981) 0.94
Cloning and analysis of Candida cylindracea lipase sequences. Gene (1993) 0.93
Temporal study of immunoglobin M seroreactivity to Borrelia burgdorferi in patients treated for Lyme borreliosis. J Clin Microbiol (1997) 0.93
Chimeric Sindbis viruses dependent on the NS3 protease of hepatitis C virus. J Virol (1997) 0.93
Statistical evaluation of the coding capacity of complementary DNA strands. Nucleic Acids Res (1984) 0.93
Transforming growth factor beta 1, interleukin-8 and interleukin-1, in non-small-cell lung tumors. Am J Respir Crit Care Med (1997) 0.92
Phosphonate ester probes for proteolytic antibodies. J Biol Chem (2001) 0.92
A new determinant of endoplasmic reticulum localization is contained in the juxtamembrane region of the ectodomain of hepatitis C virus glycoprotein E1. J Biol Chem (2000) 0.92
In vitro interactions of PGE and cAMP with murine and human erythroid precursors. Blood (1980) 0.91
Multiple determinants influence complex formation of the hepatitis C virus NS3 protease domain with its NS4A cofactor peptide. Biochemistry (1999) 0.91